EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Shexiang Huayu Xingnao Granule Alleviates Intracerebral Hemorrhage via PI3K/AKT‐Mediated Neuroinflammation Regulation: Integrated Network Pharmacology and Experimental Validation

Yuan RuKui, Wang MingLi, Li Chun, Chen MeiJuan, Yuan Yuan

Brain and Behavior · 2026-11 · 16 (11)

DOI: 10.1002/brb3.71853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 30.10.2026. Verfasst von Yuan RuKui und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Drugs, Chinese Herbal, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central Finance Traditional Chinese Medicine Inheritance and Development Subsidy Project, Science and Technology Project of the Sichuan Administration of Traditional Chinese Medicine, Luzhou Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Employing network pharmacology prediction combined with experimental validation, this research elucidated the underlying mechanisms of Shexiang Huayu Xingnao granules (SXHY) against intracerebral hemorrhage (ICH).

Methods

Potential targets and related signaling pathways of SXHY acting on ICH were predicted through network pharmacology. An autologous blood injection‐induced rat ICH model was established, with simvastatin as the positive control drug. The therapeutic effects of SXHY were evaluated using neurological function scores, brain water content, superoxide dismutase (SOD), catalase, malondialdehyde activity, and brain tissue hemorrhage area. Mechanism studies used a lipopolysaccharide‐stimulated BV‐2 microglial cell model, assessing inflammatory mediator expression profiles and PI3K/AKT pathway modulation through RT‐qPCR and Western blot analysis.

Results

Network pharmacology analysis revealed 360 common SXHY‐ICH targets, with 10 core targets (including TNF, AKT1, IL‐6, and IL‐1β) significantly enriched in the PI3K/AKT, AGE‐RAGE, and MAPK pathways; molecular docking further demonstrated potent binding of the key component stigmasterol to TNF‐α (binding energy: −9.125 kcal/mol) and IL‐6 (binding energy: −8.57 kcal/mol). Animal experiments showed within‐group improvements in neurological function from day 2 to day 3 post‐ICH in SXHY groups. The observed proportions of animals with improved neurological scores were 88.9% (low‐dose), 83.3% (high‐dose), 70.0% (model), and 62.5% (simvastatin). However, no statistically significant between‐group differences were observed at day 3 ( p > 0.05). It also reduced brain edema (high dose: 78.0 ± 0.7% vs. model: 80.5 ± 1.0%, p < 0.01) and significantly decreased hematoma area (high dose: 0.35 ± 0.50 mm 2 vs. model: 1.02 ± 0.93 mm 2 , p < 0.05); meanwhile, it significantly increased SOD activity (high dose: 68.7 ± 11.3 U/mg protein vs. model: 37.3±14.1 U/mg protein, p < 0.01). Cell experiments further confirmed that SXHY mediates anti‐inflammatory activity through modulation of PI3K/AKT signaling, including reduced p‐PI3K/GAPDH ( p < 0.01), downregulation of proinflammatory cytokines TNF‐α/IL‐6/IL‐1β mRNA ( p < 0.01), and upregulation of anti‐inflammatory cytokine IL‐10 mRNA ( p < 0.05).

Conclusion

SXHY may alleviate post‐ICH brain injury by inhibiting neuroinflammation throu modulation of the PI3K/AKT pathway. The results provide new mechanistic evidence for traditional Chinese medicine interventions against ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral HemorrhageDrugs, Chinese HerbalProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesNeuroinflammatory DiseasesAnimalsNetwork PharmacologyRatsSignal TransductionMaleRats, Sprague-DawleyDisease Models, AnimalNeuroprotective AgentsMicroglia

Stichwörter der Autor:innen

PI3K/AKT pathwayShexiang Huayu Xingnao granulesintracerebral hemorrhagenetwork pharmacologyneuroinflammationtraditional Chinese medicine

Substanzen

Drugs, Chinese HerbalProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesNeuroprotective Agents

Autor:innen und Institutionen

  • The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China.
  • Compounded Infusion Quality Testing Analysis and Precision Medication Technological Innovation Key Laboratory of Luzhou, Luzhou, China.
  • School of Pharmacy, Southwest Medical University, Luzhou, China.

Förderung

  • Central Finance Traditional Chinese Medicine Inheritance and Development Subsidy Project
  • Science and Technology Project of the Sichuan Administration of Traditional Chinese Medicine
  • Luzhou Science and Technology Plan Project

Zitieren

APA

RuKui, Y., MingLi, W., Chun, L., MeiJuan, C., & Yuan, Y. (2026). Shexiang Huayu Xingnao Granule Alleviates Intracerebral Hemorrhage via PI3K/AKT‐Mediated Neuroinflammation Regulation: Integrated Network Pharmacology and Experimental Validation. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71853

Vancouver

RuKui Y, MingLi W, Chun L, MeiJuan C, Yuan Y. Shexiang Huayu Xingnao Granule Alleviates Intracerebral Hemorrhage via PI3K/AKT‐Mediated Neuroinflammation Regulation: Integrated Network Pharmacology and Experimental Validation. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71853

BibTeX
@article{RuKui2026,
  author = {RuKui, Yuan and MingLi, Wang and Chun, Li and MeiJuan, Chen and Yuan, Yuan},
  title = {Shexiang Huayu Xingnao Granule Alleviates Intracerebral Hemorrhage via PI3K/AKT‐Mediated Neuroinflammation Regulation: Integrated Network Pharmacology and Experimental Validation},
  journal = {Brain and Behavior},
  year = {2026},
  volume = {16},
  number = {11},
  doi = {10.1002/brb3.71853}
}
Kostenlos starten →